@article {Eyal74, author = {Nir Eyal}, title = {How to keep high-risk studies ethical: classifying candidate solutions}, volume = {43}, number = {2}, pages = {74--77}, year = {2017}, doi = {10.1136/medethics-2016-103428}, publisher = {Institute of Medical Ethics}, abstract = {This article lays out a wide spectrum of candidate ethical solutions for the challenge on which this JME symposium focuses: the benefit:risk ratio challenge to some early-phase HIV cure and remission studies. These candidate solutions fall into four categories: ones that seek to reduce risks in early-phase HIV cure and remission studies, ones that enhance the benefits for these studies{\textquoteright} participants (or show that those were adequate in the first place), ones that focus on participants{\textquoteright} free and informed consent to participate and ones according to whom the large benefits to non-participants can defeat considerations about individual participant net risks. In so doing, this article also structures the rest of the symposium.}, issn = {0306-6800}, URL = {https://jme.bmj.com/content/43/2/74}, eprint = {https://jme.bmj.com/content/43/2/74.full.pdf}, journal = {Journal of Medical Ethics} }